Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody-positive Patients

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2010 Oct 28

PMID 20978875

Citations 70

Authors

Michelle Petri

Affiliations

Soon will be listed here.

Abstract

Hydroxychloroquine is used extensively in the treatment of systemic lupus erythematosus, not only for its benefit for cutaneous and musculoskeletal lupus, but also for its role in preventing flares, preventing renal and central nervous system lupus, and improving survival rates. Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus. This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies.

Citing Articles

Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.

Snow Z, Seely K, Barrett S, Pecha J, Goldhardt R Curr Ophthalmol Rep. 2024; 12(3):38-48.

PMID: 39371107 PMC: 11452169. DOI: 10.1007/s40135-024-00321-6.

Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus.

Grimaldi L, Duchemin T, Hamon Y, Buchard A, Benichou J, Abenhaim L JAMA Netw Open. 2024; 7(8):e2432190.

PMID: 39212983 PMC: 11364994. DOI: 10.1001/jamanetworkopen.2024.32190.

Antimalarial Drugs at the Intersection of SARS-CoV-2 and Rheumatic Diseases: What Are the Potential Opportunities?.

Abisheva S, Rutskaya-Moroshan K, Nuranova G, Batyrkhan T, Abisheva A Medicina (Kaunas). 2024; 60(7).

PMID: 39064600 PMC: 11279047. DOI: 10.3390/medicina60071171.

Serum Advanced Glycation End Products and Their Soluble Receptor as New Biomarkers in Systemic Lupus Erythematosus.

Carrion-Barbera I, Triginer L, Tio L, Perez-Garcia C, Ribes A, Abad V Biomedicines. 2024; 12(3).

PMID: 38540223 PMC: 10968350. DOI: 10.3390/biomedicines12030610.

Evaluation of early retinal changes in patients on long-term hydroxychloroquine using optical coherence tomography angiography.

Zhao H, Pan M, Liu Y, Cheng F, Shuai Z Ther Adv Drug Saf. 2024; 15:20420986231225851.

PMID: 38300766 PMC: 10823852. DOI: 10.1177/20420986231225851.

References

Segal-Eiras A, Segura G, Babini J, Arturi A, Fraguela J, Marcos J . Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis. J Rheumatol. 1985; 12(1):87-9. View

MADOW B . Use of antimalarial drugs as "desludging" agents in vascular disease processes. J Am Med Assoc. 1960; 172:1630-3. DOI: 10.1001/jama.1960.03020150054010. View

Sanchez-Guerrero J, Fragoso-Loyo H, Neuwelt C, Wallace D, Ginzler E, Sherrer Y . Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008; 35(8):1567-75. View

Goldman F, Gilman A, Hollenback C, Kato R, Premack B, Rawlings D . Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000; 95(11):3460-6. View

Bird H, Harkness J, WRIGHT V . Some rheological properties of blood during anti-rheumatoid therapy. Pharmatherapeutica. 1981; 3(1):36-9. View

Ernst E, Rose M, Lee R . Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect. Pharmatherapeutica. 1984; 4(1):48-52. View

Doring Y, Hurst J, Lorenz M, Prinz N, Clemens N, Drechsler M . Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology. 2009; 215(3):230-41. DOI: 10.1016/j.imbio.2009.03.002. View

Carter A, EBAN R, Perrett R . Prevention of postoperative deep venous thrombosis and pulmonary embolism. Br Med J. 1971; 1(5744):312-4. PMC: 1794857. DOI: 10.1136/bmj.1.5744.312. View

Winocour P, Kinlough-Rathbone R, Mustard J . The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemost. 1981; 45(3):257-62. View

10.

Lafyatis R, York M, Marshak-Rothstein A . Antimalarial agents: closing the gate on Toll-like receptors?. Arthritis Rheum. 2006; 54(10):3068-70. DOI: 10.1002/art.22157. View

11.

Raschi E, Borghi M, Grossi C, Broggini V, Pierangeli S, Meroni P . Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus. 2008; 17(10):937-42. DOI: 10.1177/0961203308095140. View

12.

Johnson R, CHARNLEY J . Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res. 1979; (144):174-7. View

13.

Wallace D, Linker-Israeli M, Hyun S, Klinenberg J, Stecher V . The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J Rheumatol. 1994; 21(2):375-6. View

14.

Chrisman O, SNOOK G, Wilson T, Short J . Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report. J Bone Joint Surg Am. 1976; 58(7):918-20. View

15.

ZIEGLER H, UNANUE E . Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A. 1982; 79(1):175-8. PMC: 345685. DOI: 10.1073/pnas.79.1.175. View

16.

Erkan D, Yazici Y, Peterson M, Sammaritano L, Lockshin M . A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002; 41(8):924-9. DOI: 10.1093/rheumatology/41.8.924. View

17.

Berman J, Girardi G, Salmon J . TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2004; 174(1):485-90. DOI: 10.4049/jimmunol.174.1.485. View

18.

Edwards M, Pierangeli S, Liu X, Barker J, Anderson G, Harris E . Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1998; 96(12):4380-4. DOI: 10.1161/01.cir.96.12.4380. View

19.

Hansen E, Jessing P, Lindewald H, Ostergaard P, Olesen T, Malver E . Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine. J Bone Joint Surg Am. 1976; 58(8):1089-93. View

20.

Rand J, Wu X, Quinn A, Chen P, Hathcock J, Taatjes D . Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008; 112(5):1687-95. PMC: 2518879. DOI: 10.1182/blood-2008-03-144204. View